Immune dysfunction in acute alcoholic hepatitis

World Journal of Gastroenterology

Volumn 21, Issue 42, 2015, Pages 11904-11913

  Dhanda, Ashwin D ^a,b,c   Collins, Peter L ^a,d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^c PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alcoholic hepatitis; Alcoholic liver disease; Gut dysbiosis; T cell exhaustion; Toll like receptors

Indexed keywords

ALCOHOL; CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; TOLL LIKE RECEPTOR; AUTACOID;

ALCOHOL LIVER DISEASE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL DAMAGE; CELL INFILTRATION; CYTOKINE RELEASE; DYSBIOSIS; GASTROINTESTINAL TRACT; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; LIVER; LYMPHOCYTIC INFILTRATION; MONOCYTE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PORTAL VEIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY BURST; SIGNAL TRANSDUCTION; STELLATE CELL; T LYMPHOCYTE; TH17 CELL; TIGHT JUNCTION; ACUTE DISEASE; ADVERSE EFFECTS; ANIMAL; BACTERIAL TRANSLOCATION; DRINKING BEHAVIOR; HEPATITIS, ALCOHOLIC; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; MORTALITY; MUCOSAL IMMUNITY; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ACUTE DISEASE; ALCOHOL DRINKING; ANIMALS; BACTERIAL TRANSLOCATION; CHEMOKINES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPATITIS, ALCOHOLIC; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION MEDIATORS; INTESTINES; LIVER; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; TH17 CELLS; TOLL-LIKE RECEPTORS;

EID: 84947461497     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i42.11904     Document Type: Article

References (84)

1. Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G, Gilmore I, Hickman M, Hudson M, Kelly D, Langford A, Lombard M, Longworth L, Martin N, Moriarty K, Newsome P, O'Grady J, Pryke R, Rutter H, Ryder S, Sheron N, Smith T. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014; 384: 1953-1997 [PMID: 25433429 DOI: 10.1016/S0140-6736(14)61838-9]
2. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006; 367: 52-56 [PMID: 16399153 DOI: 10.1016/S0140-6736(06)67924-5]
3. NHS Health and Social Care Information Centre. NHS, 2014
4. World Health Organsiation WHO. Global status report on alcohol and health-2014 edition. World Health Organisation, 2014
5. Sandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study. J Hepatol 2011; 54: 760-764 [PMID: 21126790 DOI: 10.1016/j.jhep.2010.07.016]
6. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-2769 [PMID: 19553649 DOI: 10.1056/NEJMra0805786]
7. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008; 27: 1167-1178 [PMID: 18363896 DOI: 10.1111/j.1365-2036.2008.03685.x]
8. Dhanda AD, Collins PL, McCune CA. Is liver biopsy necessary in the management of alcoholic hepatitis? World J Gastroenterol 2013; 19: 7825-7829 [PMID: 24307775 DOI: 10.3748/wjg.v19. i44.7825]
9. Mookerjee RP, Lackner C, Stauber R, Stadlbauer V, Deheragoda M, Aigelsreiter A, Jalan R. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J Hepatol 2011; 55: 1103-1111 [PMID: 21376092 DOI: 10.1016/j.jhep.2011.02.021]
10. Wells JT, Said A, Agni R, Tome S, Hughes S, Dureja P, Lucey MR. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl 2007; 13: 1728-1735 [PMID: 18044757 DOI: 10.1002/lt.21298]
11. Wang HJ, Gao B, Zakhari S, Nagy LE. Inflammation in alcoholic liver disease. Annu Rev Nutr 2012; 32: 343-368 [PMID: 22524187 DOI: 10.1146/annurev-nutr-072610-145138]
12. Gustot T, Maillart E, Bocci M, Surin R, Trépo E, Degré D, Lucidi V, Taccone FS, Delforge ML, Vincent JL, Donckier V, Jacobs F, Moreno C. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol 2014; 60: 267-274 [PMID: 24055548 DOI: 10.1016/j.jhep.2013.09.011]
13. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397 [PMID: 15122768 DOI: 10.1002/hep.20206]
14. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-854 [PMID: 23489011 DOI: 10.1111/apt.12279]
15. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-425 [PMID: 12663232]
16. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960 [PMID: 18848937 DOI: 10.1053/j.gastro.2008.08.057]
17. Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci 2012; 57: 1664-1671 [PMID: 22388710 DOI: 10.1007/s10620-012-2097-4]
18. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, Lebrec D, Moreno C, Talbodec N, Paupard T, Naveau S, Silvain C, Pageaux GP, Sobesky R, Canva-Delcambre V, Dharancy S, Salleron J, Dao T. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA 2013; 310: 1033-1041 [PMID: 24026598 DOI: 10.1001/jama.2013.276300]
19. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015; 372: 1619-1628 [PMID: 25901427 DOI: 10.1056/NEJMoa1412278]
20. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan TR. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260 [PMID: 20940288 DOI: 10.1136/gut.2010.224097]
21. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, CanvaDelcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009; 137: 541-548 [PMID: 19445945 DOI: 10.1053/j.gastro.2009.04.062]
22. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]
23. Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol 2014; 20: 17756-17772 [PMID: 25548474 DOI: 10.3748/wjg.v20.i47.17756]
24. Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010; 3: 178-185 [PMID: 20716942 DOI: 10.4161/oxim.3.3.12288]
25. Thurman RG, Bradford BU, Iimuro Y, Frankenberg MV, Knecht KT, Connor HD, Adachi Y, Wall C, Arteel GE, Raleigh JA, Forman DT, Mason RP. Mechanisms of alcohol-induced hepatotoxicity: studies in rats. Front Biosci 1999; 4: e42-e46 [PMID: 10417060]
26. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105 [PMID: 21254165 DOI: 10.1002/hep.24018]
27. Bode JC, Bode C, Heidelbach R, Dürr HK, Martini GA. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984; 31: 30-34 [PMID: 6698486]
28. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-682 [PMID: 19038698 DOI: 10.1016/j.alcohol.2008.08.006]
29. Lata J, Novotný I, Príbramská V, Juránková J, Fric P, Kroupa R, Stibůrek O. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19: 1111-1113 [PMID: 17998837 DOI: 10.1097/MEG.0b013e3282efa40e]
30. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945-951 [PMID: 18433921 DOI: 10.1016/j.jhep.2008.02.015]
31. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, Kwasny M, Lau CK, Keshavarzian A. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302: G966-G978 [PMID: 22241860 DOI: 10.1152/ajpgi.00380.2011]
32. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 218-224 [PMID: 7806045]
33. Ma TY, Nguyen D, Bui V, Nguyen H, Hoa N. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol 1999; 276: G965-G974 [PMID: 10198341]
34. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799-809 [PMID: 19855405 DOI: 10.1038/nri2653]
35. Wang Y, Kirpich I, Liu Y, Ma Z, Barve S, McClain CJ, Feng W. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol 2011; 179: 2866-2875 [PMID: 22093263 DOI: 10.1016/j.ajpath.2011.08.039]
36. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcoholinduced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009; 43: 163-172 [PMID: 19251117 DOI: 10.1016/j.alcohol.2008.12.009]
37. Parlesak A, Schäfer C, Schütz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcoholinduced liver disease. J Hepatol 2000; 32: 742-747 [PMID: 10845660]
38. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010; 16: 1321-1329 [PMID: 20238398]
39. Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M, Delzenne NM, de Timary P. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain Behav Immun 2012; 26: 911-918 [PMID: 22521198 DOI: 10.1016/j.bbi.2012.04.001]
40. Clinicaltrials.gov. (accessed 24 Mar 2015). United States National Institutes of Health. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01501162
41. West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 2006; 22: 409-437 [PMID: 16822173 DOI: 10.1146/annurev.cellbio.21.122303.115827]
42. Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 2010; 67: 4109-4134 [PMID: 20680392 DOI: 10.1007/s00018-010-0464-x]
43. Gustot T, Lemmers A, Moreno C, Nagy N, Quertinmont E, Nicaise C, Franchimont D, Louis H, Devière J, Le Moine O. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006; 43: 989-1000 [PMID: 16628628 DOI: 10.1002/hep.21138]
44. Stadlbauer V, Mookerjee RP, Wright GA, Davies NA, Jürgens G, Hallström S, Jalan R. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G15-G22 [PMID: 19033535 DOI: 10.1152/ajpgi.90512.2008]
45. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Tolllike receptor 4 is involved in the mechanism of early alcoholinduced liver injury in mice. Hepatology 2001; 34: 101-108 [PMID: 11431739 DOI: 10.1053/jhep.2001.25350]
46. Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, Yamashina S, Schemmer P, Kitamura T, Oide H, Takei Y, Hirose M, Shimizu H, Miyazaki A, Brenner DA, Sato N, Thurman RG. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol 2000; 15 Suppl: D20-D25 [PMID: 10759216]
47. Inokuchi S, Tsukamoto H, Park E, Liu ZX, Brenner DA, Seki E. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res 2011; 35: 1509-1518 [PMID: 21463341 DOI: 10.1111/j.1530-0277.2011.01487.x]
48. Wang Y, Hu Y, Chao C, Yuksel M, Colle I, Flavell RA, Ma Y, Yan H, Wen L. Role of IRAK-M in alcohol induced liver injury. PLoS One 2013; 8: e57085 [PMID: 23437317 DOI: 10.1371/journal. pone.0057085]
49. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-920 [PMID: 2339855]
50. Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 1993; 18: 576-580 [PMID: 8359798]
51. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13: 267-276 [PMID: 1995437]
52. Pastorino JG, Hoek JB. Ethanol potentiates tumor necrosis factoralpha cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition. Hepatology 2000; 31: 1141-1152 [PMID: 10796891 DOI: 10.1053/he.2000.7013]
53. Thakur V, Pritchard MT, McMullen MR, Wang Q, Nagy LE. Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNFalpha production. J Leukoc Biol 2006; 79: 1348-1356 [PMID: 16554353 DOI: 10.1189/jlb.1005613]
54. Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol 2004; 173: 3589-3593 [PMID: 15356101]
55. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577-594.e1 [PMID: 25066692 DOI: 10.1053/j.gastro.2014.06.043]
56. Maltby J, Wright S, Bird G, Sheron N. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. Hepatology 1996; 24: 1156-1160 [PMID: 8903391 DOI: 10.1053/jhep.1996.v24. pm0008903391]
57. Bajt ML, Farhood A, Jaeschke H. Effects of CXC chemokines on neutrophil activation and sequestration in hepatic vasculature. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1188-G1195 [PMID: 11668027]
58. Affò S, Dominguez M, Lozano JJ, Sancho-Bru P, Rodrigo-Torres D, Morales-Ibanez O, Moreno M, Millán C, Loaeza-del-Castillo A, Altamirano J, García-Pagán JC, Arroyo V, Ginès P, Caballería J, Schwabe RF, Bataller R. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut 2013; 62: 452-460 [PMID: 22637703 DOI: 10.1136/gutjnl-2011-301146]
59. Gao B, Xu M. Chemokines and alcoholic hepatitis: are chemokines good therapeutic targets? Gut 2014; 63: 1683-1684 [PMID: 24515805 DOI: 10.1136/gutjnl-2013-306603]
60. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-949 [PMID: 17676045 DOI: 10.1038/ni1496]
61. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-350 [PMID: 17375096 DOI: 10.1038/ni0407-345]
62. Gao B, Waisman A. Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone. Gastroenterology 2012; 143: 536-539 [PMID: 22842060 DOI: 10.1053/j.gastro.2012.07.031]
63. Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49: 646-657 [PMID: 19177575 DOI: 10.1002/hep.22680]
64. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957 [PMID: 17676044 DOI: 10.1038/ni1497]
65. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204: 1849-1861 [PMID: 17635957 DOI: 10.1084/jem.20070663]
66. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007; 204: 2803-2812 [PMID: 18025126 DOI: 10.1084/jem.20071397]
67. Affò S, Morales-Ibanez O, Rodrigo-Torres D, Altamirano J, Blaya D, Dapito DH, Millán C, Coll M, Caviglia JM, Arroyo V, Caballería J, Schwabe RF, Ginès P, Bataller R, Sancho-Bru P. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 2014; 63: 1782-1792 [PMID: 24415562 DOI: 10.1136/gutjnl-2013-306098]
68. Støy S, Sandahl TD, Dige AK, Agnholt J, Rasmussen TK, Grønbaek H, Deleuran B, Vilstrup H. Highest frequencies of interleukin-22-producing T helper cells in alcoholic hepatitis patients with a favourable short-term course. PLoS One 2013; 8: e55101 [PMID: 23372820 DOI: 10.1371/journal.pone.0055101]
69. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, Gao B. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010; 52: 1291-1300 [PMID: 20842630 DOI: 10.1002/hep.23837]
70. Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, Abreu MT, Unutmaz D, Sundrud MS. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014; 211: 89-104 [PMID: 24395888 DOI: 10.1084/jem.20130301]
71. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, Piganelli JD, Ray A, Kolls JK. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089-4097 [PMID: 18768865]
72. Schewitz-Bowers LP, Lait PJ, Copland DA, Chen P, Wu W, Dhanda AD, Vistica BP, Williams EL, Liu B, Jawad S, Li Z, Tucker W, Hirani S, Wakabayashi Y, Zhu J, Sen N, Conway-Campbell BL, Gery I, Dick AD, Wei L, Nussenblatt RB, Lee RW. Glucocorticoidresistant Th17 cells are selectively attenuated by cyclosporine A. Proc Natl Acad Sci USA 2015; 112: 4080-4085 [PMID: 25775512 DOI: 10.1073/pnas.1418316112]
73. Hawthorne AB. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003; 15: 239-244 [PMID: 12610317 DOI: 10.1097/01.meg.0000049996.68425.4f]
74. Dhanda AD, di Mambro AJ, Hunt VL, McCune CA, Dayan CM, Dick AD, Lee RW, Collins PL. Long-term outcome in patients with severe alcoholic hepatitis can be reliably determined using an in vitro measure of steroid sensitivity. Hepatology 2015; 61: 1099 [PMID: 24811769 DOI: 10.1002/hep.27211]
75. Linsley PS. Distinct roles for CD28 and cytotoxic T lymphocyteassociated molecule-4 receptors during T cell activation? J Exp Med 1995; 182: 289-292 [PMID: 7543133]
76. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547 [PMID: 7584144]
77. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704 [PMID: 18173375 DOI: 10.1146/annurev.immunol.26.021607.090331]
78. Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol 2013; 4: 449. [PMID: 24339828 DOI: 10.3389/fimmu.2013.00449]
79. Markwick LJ, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, Manakkat Vijay GK, Vergis N, Thursz M, Evans A, Wright G, Tarff S, O'Grady J, Williams R, Shawcross DL, Chokshi S. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology 2015; 148: 590-602.e10 [PMID: 25479137 DOI: 10.1053/j.gastro.2014.11.041]
80. Thorgeirsson SS, Grisham JW. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology 2006; 43: 2-8 [PMID: 16374844 DOI: 10.1002/hep.21015]
81. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colonystimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991; 163: 579-583 [PMID: 1704903]
82. Spahr L, Lambert JF, Rubbia-Brandt L, Chalandon Y, Frossard JL, Giostra E, Hadengue A. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology 2008; 48: 221-229 [PMID: 18537187 DOI: 10.1002/hep.22317]
83. Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, Sakhuja P, Sarin SK. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 505-512.e1 [PMID: 22119930 DOI: 10.1053/j.gastro.2011.11.027]
84. Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014; 109: 1417-1423 [PMID: 24935272 DOI: 10.1038/ajg.2014.154]